Literature DB >> 2124694

beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease.

E Z Baum1, G A Bebernitz, Y Gluzman.   

Abstract

A "cleavage cassette" specifying a decapeptide human immunodeficiency virus (HIV) protease cleavage site was introduced into six different locations of beta-galactosidase (beta-D-galactoside galactohydrolase, EC 3.2.1.23) in Escherichia coli. Four of these constructs retained beta-galactosidase activity despite the insertion of the cleavage cassette. Of these four constructs, one was cleaved by HIV protease, resulting in the inactivation of beta-galactosidase both in vivo and in vitro. This cleavage was inhibited by pepstatin A, a known inhibitor of HIV protease. Thus, beta-galactosidase has been converted into an easily assayed substrate for HIV protease. An analogous construct of beta-galactosidase containing a polio protease cleavage site was cleaved likewise by polio protease, suggesting that this system may be generic for monitoring cleavage by a variety of proteases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124694      PMCID: PMC55307          DOI: 10.1073/pnas.87.24.10023

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Cleavage of synthetic peptides by purified poliovirus 3C proteinase.

Authors:  P V Pallai; F Burkhardt; M Skoog; K Schreiner; P Bax; K A Cohen; G Hansen; D E Palladino; K S Harris; M J Nicklin
Journal:  J Biol Chem       Date:  1989-06-15       Impact factor: 5.157

2.  HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins.

Authors:  P L Darke; R F Nutt; S F Brady; V M Garsky; T M Ciccarone; C T Leu; P K Lumma; R M Freidinger; D F Veber; I S Sigal
Journal:  Biochem Biophys Res Commun       Date:  1988-10-14       Impact factor: 3.575

3.  Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease.

Authors:  S Billich; M T Knoop; J Hansen; P Strop; J Sedlacek; R Mertz; K Moelling
Journal:  J Biol Chem       Date:  1988-12-05       Impact factor: 5.157

4.  Synthetic non-peptide inhibitors of HIV protease.

Authors:  J J Blumenstein; T D Copeland; S Oroszlan; C J Michejda
Journal:  Biochem Biophys Res Commun       Date:  1989-09-15       Impact factor: 3.575

5.  Effects of amino acid substitutions at the active site in Escherichia coli beta-galactosidase.

Authors:  C G Cupples; J H Miller
Journal:  Genetics       Date:  1988-11       Impact factor: 4.562

6.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

Authors:  S Seelmeier; H Schmidt; V Turk; K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Continuous spectrophotometric assay for retroviral proteases of HIV-1 and AMV.

Authors:  N T Nashed; J M Louis; J M Sayer; E M Wondrak; P T Mora; S Oroszlan; D M Jerina
Journal:  Biochem Biophys Res Commun       Date:  1989-09-15       Impact factor: 3.575

8.  Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.

Authors:  G B Dreyer; B W Metcalf; T A Tomaszek; T J Carr; A C Chandler; L Hyland; S A Fakhoury; V W Magaard; M L Moore; J E Strickler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Peptide substrates and inhibitors of the HIV-1 protease.

Authors:  M L Moore; W M Bryan; S A Fakhoury; V W Magaard; W F Huffman; B D Dayton; T D Meek; L Hyland; G B Dreyer; B W Metcalf
Journal:  Biochem Biophys Res Commun       Date:  1989-03-15       Impact factor: 3.575

10.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides.

Authors:  H G Kräusslich; R H Ingraham; M T Skoog; E Wimmer; P V Pallai; C A Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

View more
  14 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Chemical complementation: a reaction-independent genetic assay for enzyme catalysis.

Authors:  Kathleen Baker; Colleen Bleczinski; Hening Lin; Gilda Salazar-Jimenez; Debleena Sengupta; Sonja Krane; Virginia W Cornish
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

3.  Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.

Authors:  N Dautin; G Karimova; A Ullmann; D Ladant
Journal:  J Bacteriol       Date:  2000-12       Impact factor: 3.490

4.  Rational design of p53, an intrinsically unstructured protein, for the fabrication of novel molecular sensors.

Authors:  Melissa L Geddie; Taryn L O'Loughlin; Kristen K Woods; Ichiro Matsumura
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

5.  Diversification and specialization of HIV protease function during in vitro evolution.

Authors:  Taryn L O'Loughlin; Dina N Greene; Ichiro Matsumura
Journal:  Mol Biol Evol       Date:  2006-01-19       Impact factor: 16.240

6.  Proteinase trapping: screening for viral proteinase mutants by alpha complementation.

Authors:  H D Liebig; T Skern; M Luderer; W Sommergruber; D Blaas; E Kuechler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

7.  HIV protease-activated molecular switches based on beta-glucuronidase and alkaline phosphatase.

Authors:  Taryn L O'Loughlin; Ichiro Matsumura
Journal:  Comb Chem High Throughput Screen       Date:  2006-05       Impact factor: 1.339

8.  Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity.

Authors:  K Lindsten; T Uhlíková; J Konvalinka; M G Masucci; N P Dantuma
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  Directed evolution of highly selective proteases by using a novel FACS-based screen that capitalizes on the p53 regulator MDM2.

Authors:  Tae Hyeon Yoo; Mark Pogson; Brent L Iverson; George Georgiou
Journal:  Chembiochem       Date:  2012-02-14       Impact factor: 3.164

Review 10.  Engineering next generation proteases.

Authors:  Mark Pogson; George Georgiou; Brent L Iverson
Journal:  Curr Opin Biotechnol       Date:  2009-08-24       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.